Citi analyst Geoff Meacham has maintained their bullish stance on BNTX stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Geoff Meacham’s rating is based on BioNTech’s strategic acquisition of CureVac, which enhances its transition into an oncology-focused company utilizing mRNA technologies. This acquisition brings in CureVac’s neoantigen cancer vaccines, complementing BioNTech’s existing programs and expanding its portfolio, particularly with the promising CVGBM vaccine for glioblastoma.
Additionally, the acquisition provides BioNTech with a diversified pipeline, reducing reliance on respiratory vaccines and mitigating seasonal and policy-related risks. The transaction terms, including the share exchange, imply a significant equity value for CureVac, and the expected share price return of 32.8% further supports the Buy rating.
Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Merck & Company. According to TipRanks, Meacham has an average return of 2.1% and a 52.82% success rate on recommended stocks.
In another report released today, Deutsche Bank also maintained a Buy rating on the stock with a $140.00 price target.